Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALERS.PA
- Price
- 24.10
- Stock movement up
- +0.10 (0.42%)
- Company name
- Eurobio Scientific SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Medical Devices
- Market cap
- 241.65M
- Ent value
- 331.47M
- Price/Sales
- 0.97
- Price/Book
- 1.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 10.08
- Forward P/E
- 21.71
- PEG
- -
- EPS growth
- -
- 1 year return
- 62.40%
- 3 year return
- 9.81%
- 5 year return
- 17.52%
- 10 year return
- 8.49%
Last updated: 2025-04-12
DIVIDENDS
ALERS.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 10.08 |
| Price to OCF | 4.87 |
| Price to FCF | 5.72 |
| Price to EBITDA | 4.27 |
| EV to EBITDA | 5.86 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.97 |
| Price to Book | 1.35 |
| EV to Sales | 1.32 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 10.03M |
| EPS (TTM) | 2.39 |
| FCF per share (TTM) | 4.21 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 250.22M |
| Gross profit (TTM) | 113.40M |
| Operating income (TTM) | 34.50M |
| Net income (TTM) | 23.97M |
| EPS (TTM) | 2.39 |
| EPS (1y forward) | 1.11 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 45.32% |
| Operating margin (TTM) | 13.79% |
| Profit margin (TTM) | 9.58% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 45.12M |
| Net receivables | 27.82M |
| Total current assets | 146.67M |
| Goodwill | 117.70M |
| Intangible assets | 1.95M |
| Property, plant and equipment | 0.00 |
| Total assets | 313.77M |
| Accounts payable | 19.12M |
| Short/Current long term debt | 93.40M |
| Total current liabilities | 54.55M |
| Total liabilities | 134.94M |
| Shareholder's equity | 178.82M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 49.60M |
| Capital expenditures (TTM) | 6.24M |
| Free cash flow (TTM) | 42.25M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 13.40% |
| Return on Assets | 7.64% |
| Return on Invested Capital | 12.34% |
| Cash Return on Invested Capital | 21.75% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 24.10 |
| Daily high | 24.66 |
| Daily low | 24.10 |
| Daily Volume | 1K |
| All-time high | 435.35 |
| 1y analyst estimate | 30.00 |
| Beta | -0.27 |
| EPS (TTM) | 2.39 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ALERS.PA | S&P500 | |
| Current price drop from All-time high | -94.46% | -12.89% |
| Highest price drop | -99.32% | -56.47% |
| Date of highest drop | 24 Dec 2018 | 9 Mar 2009 |
| Avg drop from high | -90.96% | -11.07% |
| Avg time to new high | 451 days | 12 days |
| Max time to new high | 4868 days | 1805 days |
COMPANY DETAILS
Marketcap
241.65M
Marketcap category
Small-cap
Description
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, a molecular test for the surveillance of heart-transplant patients; cell culture media, molecular biology reagents, and proprietary antibodies; TQS (Tetanus Quick Stick) for the evaluation of patients' immune status against tetanus; and EBX molecular biology family, which includes a range of tests for identifying various pathogens responsible for infectious diseases and assessing the magnitude of the infection. The company also develops other diagnostic products using molecular biology. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
Employees
329
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Amidst a backdrop of uncertainty in the European markets, with the pan-European STOXX Europe 600 Index recently declining by 1.23% due to concerns over U.S. trade tariffs and monetary policy, investor...
March 18, 2025
EUROBIO SCIENTIFIC INCREASES ITS FOOTPRINT IN ITALY Signing of the acquisition of Life Science unit of Voden Medical Instruments SpaCompletion of the acquisition of Quimark SRLDecision of supplier T2 ...
March 12, 2025
Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners Paris, 1...
December 19, 2024
As global markets react to the recent U.S. Federal Reserve rate cut, European indices have shown mixed results, with France's CAC 40 Index posting modest gains. Amid this evolving economic landscape, ...
September 26, 2024
RESULTS FOR THE 1ST HALF OF 2024 Revenues up 12% on a like-for-like basis (24% overall)Stable adjusted EBITDA1 and operating profitNet financial debt down slightly to €1.6m, with cash of €86.6mPropose...
September 24, 2024
As the European Central Bank's recent rate cut aims to bolster economic growth, France's CAC 40 Index has seen a notable uptick, reflecting positive sentiment in the broader market. In this context of...
September 19, 2024
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS Paris, August 2nd, 2024 –7:30 am Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro...
August 2, 2024
NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO ANY US PERSON, OR TO ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION...
July 31, 2024
NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO ANY US PERSON, OR TO ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION...
July 31, 2024
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT®
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT® Expansion in the oncology segmentDevelopment of Eurobio Scientific proprietary product portfolioInc...
May 7, 2024